September 9, 2010 — The biomarker troponin I (TNI) can help clinicians identify which breast cancer patients receiving trastuzumab (Herceptin, Genentech/Roche) are at risk for heart damage and which ...

Long after breast cancer treatment with trastuzumab and anthracycline, patients can show signs of cardiac damage and may need long-term cardiac surveillance.

What has caused this young woman in her 20s to develop heart palpitations and shortness of breath? That's what Xuhong Geng, MD, of Fourth Hospital of Hebei Medical University in China, and colleagues ...

Tailoring Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: Recent Advances and Strategies This review critically analyzes the incidence of ...

Herceptin, crucial for HER2-positive breast cancer, poses significant heart risks, requiring careful cardiac monitoring during treatment. Radiation therapy, despite breath-hold techniques, can cause ...

One expert explained the common side effects at every line of treatment for metastatic HER2-positive breast cancer during the CURE® Educated Patient® Metastatic Breast Cancer Summit. There are side ...

LOS ANGELES (Reuters) - Combining targeted breast cancer treatment Herceptin with a more frequent chemotherapy regimen reduces the risk of heart problems related to the Genentech drug, according to ...